Trial Results, New Facilities, Approved Labels, Spinoffs, and M&As Support Long-Term Growth Strategies - Research Report on

  Trial Results, New Facilities, Approved Labels, Spinoffs, and M&As Support
 Long-Term Growth Strategies - Research Report on Pfizer, Johnson & Johnson,
                        Merck, Zoetis, and AstraZeneca

PR Newswire

NEW YORK, July 4, 2013

NEW YORK, July 4, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Wall Street Reports announced new research reports highlighting Pfizer
Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK),
Zoetis Inc. (NYSE: ZTS), and AstraZeneca PLC (NYSE: AZN). Today's readers may
access these reports free of charge - including full price targets, industry
analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

On June 30, 2013, Pfizer Inc. (Pfizer) and Bristol-Myers Squibb Company
announced the results of the six-month Phase III AMPLIFY trial of 5,395
patients with acute venous thromboembolism (VTE), which includes symptomatic
deep vein thrombosis (DVT) and/or pulmonary embolism (PE). Pfizer reported
that the single-agent Eliquis achieved the primary efficacy endpoint of
non-inferiority to current standard of care (initial parenteral enoxaparin
treatment overlapped with warfarin therapy) in the reduction of the composite
endpoint of recurrent symptomatic VTE or VTE-related death. "The study results
showed that apixaban, as a single-agent, has comparable efficacy with
significantly fewer major bleeding events with respect to the standard of
care. These results complement the previously published results for the
AMPLIFY-EXT study," said Dr. Giancarlo Agnelli, Professor of Internal
Medicine, University of Perugia, Italy; Director of the Department of Internal
and Cardiovascular Medicine and Stroke-Unit, University Hospital, Perugia,
Italy; and Lead Investigator of the study. "Together these studies represent
exciting data in the field of VTE treatment and indicate that apixaban may
offer an important potential alternative in both acute and extended
anticoagulation therapy for VTE patients."

The Full Research Report on Pfizer Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.WSReports.com/r/full_research_report/db02_PFE]

--

Johnson & Johnson Research Report

On June 27, 2013, Johnson & Johnson announced the opening of its Johnson &
Johnson Innovation Center in Boston. According to the Company, the Boston
Center is the third out of four regional hubs being established in the world's
leading life science hotspots. Paul Stoffels, M.D., Chief Scientific Officer
and Worldwide Chairman, Pharmaceuticals at Johnson & Johnson, commented, "The
East Coast significance as a hotbed for life sciences innovation grounded in
collaboration is indisputable and continues to grow. With the establishment of
our Boston Innovation Center, we look forward to further fostering
collaboration with some of the world's leading scientists, renowned academic
centers, and influential entrepreneurs to enable future innovations that will
advance human health." The Full Research Report on Johnson & Johnson -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.WSReports.com/r/full_research_report/0ba3_JNJ]

--

Merck & Co. Inc. Research Report

On July 1, 2013, Merck & Co. Inc. (Merck) announced that the new labeling for
ISENTRESS (raltegravir) film-coated tablets has been approved by the US Food
and Drug Administration (FDA). Merck stated that ISENTRESS is an integrase
inhibitor for the treatment of HIV-1 infection in adult patients as part of
combination HIV therapy. Jürgen Rockstroh, M.D., University of Bonn,
Bonn-Venusberg, Germany, stated, "As the care of HIV evolves, ISENTRESS
continues to be an important treatment option for adult patients with HIV-1."
Daria Hazuda, Ph.D., Vice President of Early Development and Discovery
Sciences Research for Infectious Diseases at Merck, commented, "Merck has been
at the forefront of HIV research for close to 30 years. The discovery of
ISENTRESS and its clinical development program are a testament to Merck's
long-term commitment to the research and development of medicines for HIV."
The Full Research Report on Merck & Co. Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.WSReports.com/r/full_research_report/400f_MRK]

--

Zoetis Inc. Research Report

On June 24, 2013, Zoetis Inc. (Zoetis) announced that it has successfully
completed its spinoff from Pfizer. Juan Ramón Alaix, CEO of Zoetis, said, "We
are setting off on the next stage in our Company's life - pursuing our own
initiatives and strategies as a fully independent company." He further added,
"I am very proud of all the Zoetis colleagues who have prepared us for this
day, while continuing to support our customers with the products, innovations
and reliable supply they expect from us. We will continue serving our
customers in ways that make a meaningful difference to their businesses and
strengthen our position as the world leader in animal health." Zoetis reported
that in accordance with the terms of the exchange offer that commenced on May
22, 2013, Pfizer has accepted shares of Pfizer stock in exchange for all of
its approximately 401 million shares of Zoetis common stock. The Full Research
Report on Zoetis Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.WSReports.com/r/full_research_report/7e28_ZTS]

--

AstraZeneca PLC Research Report

On June 28, 2013, AstraZeneca PLC (AstraZeneca) announced that it has
completed the acquisition of Pearl Therapeutics and now owns 100% shares of
the company. AstraZeneca stated that this acquisition provides the Company
access to a potential new treatment for chronic obstructive pulmonary disease
(COPD), currently in late-stage development, and inhaler and formulation
technology that provides a platform for future combination products. The Full
Research Report on AstraZeneca PLC - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.WSReports.com/r/full_research_report/02c7_AZN]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.